Key result
Post-MI beta-blocker therapy lacks an established optimal duration for patients with normal LVEF.
Why the study?
The appropriate duration of beta-blocker therapy remains unknown in post-acute coronary syndrome patients with normal LVEF, and there is no clear time limit for those without angina, arrhythmia, or hypertension.
Do β-blockers prevent heart failure and major adverse cardiac events in patients post myocardial infarction?
Do β-blockers prevent heart failure and major adverse cardiac events in patients post myocardial infarction?
This review emphasizes the ongoing uncertainty regarding the optimal duration of beta-blocker therapy for secondary prevention in post-myocardial infarction patients with normal ejection fraction.
Answers are grounded in this paper and cite their sources.
Uncertainty on beta-blocker duration post-MI with normal LVEF persists; leaves open questions on HF and MACE prevention.
β-blockers have been widely utilized as a part of acute myocardial infarction (AMI) treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following myocardial infarction have a higher chance of surviving. Although many patients benefited from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction, chronic pulmonary disease, and elderly people. In individuals with the post-acute coronary syndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of betablocker therapy is still unknown. There is also no time limit for those without angina and those who do not need β-blockers for arrhythmia or hypertension. Interestingly, β-blockers have been prescribed for more than four decades. The novel mechanism of action on cellular compartments has been found continually, which opens a new way for their potential application in cardiac failure and other cardiac events like post-myocardial infarction. Here, in this review, we studied β-blocker usage in these circumstances and the current recommendations for β-blocker use from clinical practice guidelines.
No takes yet. Share an insight, caveat, or question.
Johri et al. (2023) conducted a review in Post-myocardial infarction. β-blockers was evaluated. Beta-blocker therapy post-myocardial infarction continues to be widely utilized, though the appropriate duration remains unknown for patients with normal left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: